The IgM antibody level against ganglioside GM2 correlates to the disease status of HIV-1-infected patients

Microbiology and Immunology

Volumn 44, Issue 5, 2000, Pages 405-410

  Wu, Xiaoshan ^a   Okada, Noriko ^a   Goto, Mieko ^b   Iwamoto, Aikichi ^b   Okada, Hidechika ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anti GM2 IgM antibody; CD4; Complement; HIV; HIV RNA

Indexed keywords

IMMUNOGLOBULIN M;

ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOLYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; RECEPTOR UPREGULATION; SEROCONVERSION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034042533     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2000.tb02514.x     Document Type: Article

References (25)

1. Dean, M., Carrington, M., Winkler, C., Huttley, G.A., Smith, M.W., Allikmets, R., Goedert, J.J., Buchbinder, S.P., Vittinghoff, E., Gomperts, E., Donfield, S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C., Detels, R., and O'Brien, S.J. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273: 1856-1862.
2. Ditzel, H.J., Barbas, S.M., Barbas, C.F., and Burton, D.R. 1994. The nature of the autoimmune antibody repertoire in human immunodeficiency virus type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 91: 3710-3714.
3. Finzi, D., Hermankova, M., and Pierson, T. 1997. Identification of a reservoir for HIV-1 patients on highly active antiretroviral therapy. Science 278: 1295-1298.
4. Furukawa, K., Akagi, T., Nagata, Y., Yamada, Y., Shimotohno, K., Cheung, N.K., Shiku, H., and Furukawa, K. 1993. GD2 ganglioside on human T-lymphotropic virus type 1-infected T cells: possible activation of beta-1.4-N-acetyl-galactosaminyltransferase gene by p40tax. Proc. Natl. Acad. Sci. U.S.A. 90: 1972-1976.
5. Galetto-Lacour, A., Yerly, S., Perneger, T.V., Baumberger, C., Hirschel, B., and Perrin, L. 1996. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. J. Infect. Dis. 173: 1388-1393.
6. Griggi, T., Bauer, R., Garofalo, T., Kukel, S., Lenti, L., Massetti, A.P., Muller, C., Sorice, M., and Pontieri, G.M. 1994. Autoantibodies against ganglioside GM3 represent a portion of anti-lymphocyte antibodies in AIDS patients. Scand. J. Immunol. 40: 77-82.
7. Klein, M.R., van Baalen, C.A., Holwerda, A.M., Kerkhof-Garde, S.R., Bende, R.J., Keet, I.P., Eeftinck-Schattenkerk, J.K., Osterhaus, A.D., Schuitemaker, H., and Miedema, F. 1995. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181: 1365-1372.
8. Livingston, P.O., Adluri, S., Helling, F., Yao, T.J., Kensil, C.R., Newman, M.J., and Marciani, D. 1994. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-key-hole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12: 1275-1280.
9. Matsuda, K., Taki, T., Hamanaka, S., Kasama, T., Rokukawa, C., Handa, S., and Yamamoto, N. 1993. Glycosphingolipid compositions of human T-lymphotropic virus type I (HTLV-I) and human immunodeficiency virus (HIV)-infected cell lines. Biochim. Biophys. Acta 1168: 123-129.
10. Mellors, J.W., Rinaldo, C.R., Gupta, P., White, R.M., Todd, J.A., and Kingsley, L.A. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-1170.
11. Misasi, R., Sorice ,M., Griggi ,T., d'Agostino, F., Garofalo, T., Masala, C., Pontieri, G.M., and Lenti, L. 1993. GM3 as a target of anti-lymphocytic ganglioside antibodies in AIDS patients. Clin. Immunol. Immunopathol. 67: 216-223.
12. Mizutamari, R.K., Kremer, L.J., Bacile, E.A., and Nores, G.A. 1998. Anti-GM1 ganglioside IgM-antibodies present in human plasma: affinity and biological activity changes in a patient with neuropathy. J. Neurosci. Res. 51: 237-242.
13. Mizutamari, R.K., Wiegandt, H., and Nores, G.A. 1994. Characterization of anti-ganglioside antibodies present in normal human plasma. J. Neuroimmunol. 50: 215-220.
14. Mulder, J., McKinney, N., Christopherson, C., Sninsky, J., Greenfield, L., and Kwok, S. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32: 292-300.
15. Nishinaka, Y., Ravinsdranath, M.H., and Irie, R.F. 1996. Development of a human monoclonal antibody to ganglioside GM2 with potential for cancer treatment. Cancer Res. 56: 5666-5671.
16. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann. Intern. Med. 126: 939-945.
17. Okada, H., Wu, X., and Okada, N. 1998. Complement mediated cytolysis and azidothymidine synergistic in HIV-1 suppression. Int. Immunol. 10: 91-95.
18. Okada, N., Wu ,X., Mizokami, M., Irie, R.F., and Okada, H. 1999. Human IgM monoclonal antibody to ganglioside GM2 and complement suppress virus propagation in ex vivo cultures of lymphocytes from HIV-1 infected patients. Microbiol. Immunol. 43: 723-727.
19. Okada, N., Wu, X., and Okada, H. 1997. Presence of IgM antibody which sensitizes HIV-1 infected cells to cytolysis by homologous complement in long-term survivors of HIV infection. Microbiol. Immunol. 41: 331-336.
20. Pedersen, C., Katzenstein ,T., Nielsen, C., Lundgren, J.D., and Gerstoft, J. 1997. Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection. JAIDS 16: 93-99.
21. Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., and Ho, D.D. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
22. Tai, T., Paulson, J.C., Cahan, L.D., and Irie, R.F. 1983. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc. Natl. Acad. Sci. U.S.A. 80: 5392-5396.
23. Winkler, C., Modi, W., Smith, M.W., Nelson, G.W., Wu, X., Carrington, M., Dean, M., Honjo, T., Tashiro, K., Yabe, D., Buchbinder, S., Vittinghoff, E., Goedert, J.J., O'Brien, T.R., Jacobson, L.P., Detels, R., Donfield, S., Willoughby, A., Gomperts, E., Vlahov, D., Phair, J. and O'Brien, S.J. 1998. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 279: 389-393.
24. Wu, X., Okada, N., Iwamori, M., and Okada, H. 1996. IgM natural antibody against an asialo-oligosaccharide, gangliotetraose (Gg4), sensitizes HIV-1 infected cells for cytolysis by homologous complement. Int. Immunol. 8: 153-158.
25. Wu, X., Okada, N., Momota, H., Irie, R.F., and Okada, H. 1999. Complement mediated anti-HIV-1 effect induced by human IgM mAb against ganglioside GM2. J. Immunol. 162: 533-539.